In another study, performed with acute lymphoblastic leukemia (ALL) and AML patients-derived cell lines, the sublines resistant to BCL-2 inhibitors (ABT-737 and its orally active analog ABT-263—navitoclax) or MDM2 antagonist SAR405838 were developed. Here, MDM2 is linked to acute lymphoblastic leukemia.